Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250

1.

A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.

Ziemssen T, Piani-Meier D, Bennett B, Johnson C, Tinsley K, Trigg A, Hach T, Dahlke F, Tomic D, Tolley C, Freedman MS.

J Med Internet Res. 2020 Feb 12;22(2):e16932. doi: 10.2196/16932.

2.

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2020.

Freedman MS, Hunter P, Ault K, Kroger A.

MMWR Morb Mortal Wkly Rep. 2020 Feb 7;69(5):133-135. doi: 10.15585/mmwr.mm6905a4.

3.

Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment.

Bose G, Freedman MS.

Mult Scler. 2020 Jan 22:1352458519887324. doi: 10.1177/1352458519887324. [Epub ahead of print]

PMID:
31965903
4.

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.

Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ, Selmaj K, Bidollari I, Chen H, Hanna J, Leigh-Pemberton R, Lopez-Bresnahan M, Lyons J, Miller C, Rezendes D, Wolinsky JS; EVOLVE-MS-2 Study Group.

CNS Drugs. 2020 Feb;34(2):185-196. doi: 10.1007/s40263-020-00700-0.

PMID:
31953790
5.

Research-to-Practice Gaps in Multiple Sclerosis Care for Patients with Subjective Cognitive, Mental Health, and Psychosocial Concerns in a Canadian Center.

Walker LAS, Gardner C, Freedman MS, MacLean H, Rush C, Bowman M.

Int J MS Care. 2019 Nov-Dec;21(6):243-248. doi: 10.7224/1537-2073.2017-090.

6.

No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon β-1a.

Freedman MS, Comi G, Coyle PK, Aldridge J, Chen L, Marhardt K, Kappos L.

Mult Scler Relat Disord. 2019 Dec 9;39:101891. doi: 10.1016/j.msard.2019.101891. [Epub ahead of print]

7.

Machine learning in secondary progressive multiple sclerosis: an improved predictive model for short-term disability progression.

Law MT, Traboulsee AL, Li DK, Carruthers RL, Freedman MS, Kolind SH, Tam R.

Mult Scler J Exp Transl Clin. 2019 Nov 6;5(4):2055217319885983. doi: 10.1177/2055217319885983. eCollection 2019 Oct-Dec.

8.

Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.

Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, Freedman MS, Gudesblatt M, Ziemssen T, Kandinov B, Bidollari I, Lopez-Bresnahan M, Nangia N, Rezendes D, Yang L, Chen H, Liu S, Hanna J, Miller C, Leigh-Pemberton R.

Mult Scler. 2019 Nov 4:1352458519881761. doi: 10.1177/1352458519881761. [Epub ahead of print]

PMID:
31680631
9.

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.

Van Wijmeersch B, Singer BA, Boster A, Broadley S, Fernández Ó, Freedman MS, Izquierdo G, Lycke J, Pozzilli C, Sharrack B, Steingo B, Wiendl H, Wray S, Ziemssen T, Chung L, Margolin DH, Thangavelu K, Vermersch P.

Mult Scler. 2019 Nov 1:1352458519881759. doi: 10.1177/1352458519881759. [Epub ahead of print]

PMID:
31675266
10.

Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.

Freedman MS, Brod S, Singer BA, Cohen BA, Hayward B, Dangond F, Coyle PK.

J Neurol. 2020 Jan;267(1):64-75. doi: 10.1007/s00415-019-09532-5. Epub 2019 Sep 26.

11.

High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS.

Thebault S, R Tessier D, Lee H, Bowman M, Bar-Or A, Arnold DL, L Atkins H, Tabard-Cossa V, Freedman MS.

Neurol Neuroimmunol Neuroinflamm. 2019 Aug 8;6(5):e598. doi: 10.1212/NXI.0000000000000598. eCollection 2019 Sep.

12.

Does Resetting the Immune System Fix Multiple Sclerosis?

Bose G, Thebault SDX, Atkins HL, Freedman MS.

Can J Neurol Sci. 2019 Sep 12:1-10. doi: 10.1017/cjn.2019.294. [Epub ahead of print]

PMID:
31511117
13.

Imaging cognitive fatigability in multiple sclerosis: objective quantification of cerebral blood flow during a task of sustained attention using ASL perfusion fMRI.

Berard JA, Fang Z, Walker LAS, Lindsay-Brown A, Osman L, Cameron I, Cruce R, Cron GO, Freedman MS, Smith AM.

Brain Imaging Behav. 2019 Aug 29. doi: 10.1007/s11682-019-00192-7. [Epub ahead of print]

PMID:
31468375
14.

Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★.

Miller AE, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS; TOPIC study group.

Mult Scler Relat Disord. 2019 Aug;33:131-138. doi: 10.1016/j.msard.2019.05.014. Epub 2019 May 24.

15.

Behavioral and Clinical Characteristics of Self-Identified Bisexual Men Living with HIV Receiving Medical Care in the United States-Medical Monitoring Project, 2009-2013.

Freedman MS, Beer L, Mattson CL, Sullivan PS, Skarbinski J.

J Homosex. 2019 Jun 7:1-19. doi: 10.1080/00918369.2019.1621553. [Epub ahead of print]

PMID:
31173564
16.

Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials.

Comi G, Miller AE, Benamor M, Truffinet P, Poole EM, Freedman MS.

Mult Scler. 2019 Jun 7:1352458519851981. doi: 10.1177/1352458519851981. [Epub ahead of print]

PMID:
31172849
17.

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.

Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group.

Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z.

18.

Effect of different doses of gadolinium contrast agent on clinical outcomes in MS.

Ackermans N, Taylor C, Tam R, Carruthers R, Kolind S, Kang H, Freedman MS, Li DK, Traboulsee AL.

Mult Scler J Exp Transl Clin. 2019 Feb 16;5(1):2055217318823796. doi: 10.1177/2055217318823796. eCollection 2019 Jan-Mar.

19.

Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.

Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE.

Biol Blood Marrow Transplant. 2019 May;25(5):845-854. doi: 10.1016/j.bbmt.2019.02.014. Epub 2019 Feb 19. Review.

20.

The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis.

Freedman MS, Duquette P, Grand'Maison F, Lee L, Vorobeychik G, Lara N, Khurana V, Nakhaipour HR, Schecter R, Haddad P.

Curr Med Res Opin. 2019 May;35(5):767-776. doi: 10.1080/03007995.2019.1565818. Epub 2019 Jan 21.

PMID:
30614288
21.

Predictors of response to opicinumab in acute optic neuritis.

Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch LJ, Leocani L, Freedman MS, Plant GT, Preiningerova JL, Ziemssen F, Massacesi L, Chai Y, Xu L; RENEW Study Investigators.

Ann Clin Transl Neurol. 2018 Aug 15;5(10):1154-1162. doi: 10.1002/acn3.620. eCollection 2018 Oct.

22.

Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.

Miller AE, Xu X, Macdonell R, Vucic S, Truffinet P, Benamor M, Thangavelu K, Freedman MS.

J Clin Neurosci. 2019 Jan;59:229-231. doi: 10.1016/j.jocn.2018.09.012. Epub 2018 Oct 20.

23.

Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis.

Bose G, Atkins HL, Bowman M, Freedman MS.

Mult Scler. 2019 Nov;25(13):1764-1772. doi: 10.1177/1352458518802544. Epub 2018 Sep 25.

PMID:
30251913
24.

gMS-Classifier1 does not predict disability progression in multiple sclerosis.

van Rossum JA, Killestein J, Villar LM, Riskind PN, Freedman MS, Teunissen C.

Mult Scler. 2019 Jun;25(7):1010-1011. doi: 10.1177/1352458518798048. Epub 2018 Aug 31. No abstract available.

25.

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE.

Brain Imaging Behav. 2019 Oct;13(5):1361-1374. doi: 10.1007/s11682-018-9942-9.

PMID:
30155789
26.

Gadolinium Deposition in Deep Brain Structures: Relationship with Dose and Ionization of Linear Gadolinium-Based Contrast Agents.

Kang H, Hii M, Le M, Tam R, Riddehough A, Traboulsee A, Kolind S, Freedman MS, Li DKB.

AJNR Am J Neuroradiol. 2018 Sep;39(9):1597-1603. doi: 10.3174/ajnr.A5751. Epub 2018 Aug 23.

27.

Tolerability and discontinuation rates in teriflunomide-treated patients. A real-world clinical experience.

Alnajashi HA, Alshamrani FJ, Freedman MS.

Neurosciences (Riyadh). 2018 Jul;23(3):204-207. doi: 10.17712/nsj.2018.3.20180003.

PMID:
30007995
28.

Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing.

Freedman MS, Selchen D, Prat A, Giacomini PS.

Can J Neurol Sci. 2018 Sep;45(5):489-503. doi: 10.1017/cjn.2018.17. Epub 2018 Jun 12. Review.

PMID:
29893652
29.

Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis.

Darlington PJ, Stopnicki B, Touil T, Doucet JS, Fawaz L, Roberts ME, Boivin MN, Arbour N, Freedman MS, Atkins HL, Bar-Or A.

Front Immunol. 2018 May 7;9:834. doi: 10.3389/fimmu.2018.00834. eCollection 2018.

30.

Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study.

Freedman MS, Morawski J, Thangavelu K.

Mult Scler J Exp Transl Clin. 2018 May 16;4(2):2055217318775236. doi: 10.1177/2055217318775236. eCollection 2018 Apr-Jun.

31.

The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis.

Burton JM, Freedman MS.

J Neuroophthalmol. 2018 Jun;38(2):210-216. doi: 10.1097/WNO.0000000000000659. Review.

PMID:
29750735
32.

Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis.

Rush CA, Atkins HL, Freedman MS.

Cold Spring Harb Perspect Med. 2019 Mar 1;9(3). pii: a029082. doi: 10.1101/cshperspect.a029082. Review.

PMID:
29610145
33.

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.

Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS.

Ann Clin Transl Neurol. 2018 Jan 30;5(3):346-356. doi: 10.1002/acn3.534. eCollection 2018 Mar.

34.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.

Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.

PMID:
29545067
35.

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.

Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M, Hartung HP, Jeffery D, Kappos L, Barkhof F, Edan G, Freedman MS, Montalbán X, Müller-Myhsok B, Hemmer B; BEYOND and BENEFIT Study Groups.

Mult Scler. 2019 Apr;25(4):565-573. doi: 10.1177/1352458518763089. Epub 2018 Mar 9.

PMID:
29521573
36.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
37.

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study.

Freedman MS, Leist TP, Comi G, Cree BA, Coyle PK, Hartung HP, Vermersch P, Damian D, Dangond F.

Mult Scler J Exp Transl Clin. 2017 Oct 9;3(4):2055217317732802. doi: 10.1177/2055217317732802. eCollection 2017 Oct-Dec.

38.

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo.

Vermersch P, Radue EW, Putzki N, Ritter S, Merschhemke M, Freedman MS.

Mult Scler J Exp Transl Clin. 2017 Sep 27;3(3):2055217317730096. doi: 10.1177/2055217317730096. eCollection 2017 Jul-Sep.

39.

Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis.

Atkins HL, Freedman MS.

Neurotherapeutics. 2017 Oct;14(4):888-893. doi: 10.1007/s13311-017-0564-5. Review.

40.

Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon β-1a in the EVIDENCE study.

Coyle PK, Reder AT, Freedman MS, Fang J, Dangond F.

J Neurol Sci. 2017 Aug 15;379:151-156. doi: 10.1016/j.jns.2017.05.052. Epub 2017 May 25.

41.

Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.

Lee H, Nakamura K, Narayanan S, Brown R, Chen J, Atkins HL, Freedman MS, Arnold DL.

Mult Scler. 2018 Jul;24(8):1055-1066. doi: 10.1177/1352458517715811. Epub 2017 Jun 15.

PMID:
28617152
42.

Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.

Metz LM, Li DKB, Traboulsee AL, Duquette P, Eliasziw M, Cerchiaro G, Greenfield J, Riddehough A, Yeung M, Kremenchutzky M, Vorobeychik G, Freedman MS, Bhan V, Blevins G, Marriott JJ, Grand'Maison F, Lee L, Thibault M, Hill MD, Yong VW; Minocycline in MS Study Team.

N Engl J Med. 2017 Jun 1;376(22):2122-2133. doi: 10.1056/NEJMoa1608889.

43.

Sodium intake and multiple sclerosis activity and progression in BENEFIT.

Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group.

Ann Neurol. 2017 Jul;82(1):20-29. doi: 10.1002/ana.24965.

44.

Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.

Sartori A, Abdoli M, Freedman MS.

J Neurol. 2017 Jun;264(6):1068-1075. doi: 10.1007/s00415-017-8487-y. Epub 2017 Apr 17.

PMID:
28417192
45.

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.

Freedman MS, Wolinsky JS, Comi G, Kappos L, Olsson TP, Miller AE, Thangavelu K, Benamor M, Truffinet P, O'Connor PW; TEMSO and TOWER Study Groups.

Mult Scler. 2018 Apr;24(4):535-539. doi: 10.1177/1352458517695468. Epub 2017 Mar 17.

46.

Immunoablation and aHSCT for aggressive multiple sclerosis - Authors' reply.

Atkins H, Freedman MS.

Lancet. 2017 Mar 4;389(10072):908. doi: 10.1016/S0140-6736(17)30592-5. No abstract available.

PMID:
28271842
47.

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.

Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R; Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group.

JAMA Neurol. 2017 Apr 1;74(4):459-469. doi: 10.1001/jamaneurol.2016.5867.

48.

Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.

Comi G, De Stefano N, Freedman MS, Barkhof F, Uitdehaag BM, de Vos M, Marhardt K, Chen L, Issard D, Kappos L.

J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):285-294. doi: 10.1136/jnnp-2016-314843. Epub 2016 Dec 30.

49.

Multiple sclerosis: Is there a safe time to discontinue therapy in MS?

Freedman MS.

Nat Rev Neurol. 2016 Dec 28;13(1):10-11. doi: 10.1038/nrneurol.2016.192. Review. No abstract available.

PMID:
28028316
50.

The evaluation of MRI diffusion values of active demyelinating lesions in multiple sclerosis.

Abdoli M, Chakraborty S, MacLean HJ, Freedman MS.

Mult Scler Relat Disord. 2016 Nov;10:97-102. doi: 10.1016/j.msard.2016.09.006. Epub 2016 Sep 28.

PMID:
27919508

Supplemental Content

Loading ...
Support Center